The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

Liang, Zhiman; Peng, Yonghua; Chen, Yue; Long, Li-Li; Luo, Hongjie; Chen, Yajun; Liang, Yanling; Tian, Yinghong; Li, Shu-Ji; Shi, Yusheng; Zhang, Xingmei

doi:10.1089/nat.2019.0812

Cited by 7 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A brain infusion cannula system (Ruiwode, Shenzhen, China) was implanted via right intracerebroventricular injection of 4-month-old male 5×FAD mice as described previously. 41 Briefly, mice were anesthetized with 4% chloral hydrate (0.2 mL per 20 g) and then fixed in stereotactic apparatus (Ruiwode) until the skull of the mice was kept parallel with the table top. After creation of a middle skin incision (0.5 cm around bregma) in the cranial skin, a cannula system was implanted in the right cerebral ventricle of the mice.…”

Section: Methodsmentioning

confidence: 99%

“…The spontaneous alternation Y maze test allows us to assess spatial working memory that is dependent on the hippocampus and was performed as described previously. 41 The experimental apparatus was made from black Plexiglas and consisted of three black 35 × 5 × 10 cm arms separated by 120°. Before and after each trial, the apparatus was cleaned with 70% ethanol and allowed to dry.…”

Section: Methodsmentioning

confidence: 99%

“…ThS staining was used to observe senile plaques in the hippocampus and cortex and was performed as described previously. 41 After a wash with PBS for 30 min, brain slices were stained in freshly prepared 0.01% solution of ThS with 50% alcohol for 8 min in the dark. Then, slices were washed twice in 50% alcohol for 5 min each time and subsequently washed twice in PBS for 5 min each time.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

The Aptamer Ob2, a novel AChE inhibitor, restores cognitive deficits and alleviates amyloidogenesis in 5×FAD transgenic mice

Liang

Luo

et al. 2022

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Aptamer Ob2, a novel AChE inhibitor, restores cognitive deficits and alleviates amyloidogenesis in 5×FAD transgenic mice

Liang

Luo

et al. 2022

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

“…Various drugs targeting BACE1 have been used to treat AD in animal studies, including small molecules and nucleic acid drugs. − An aptamer is a short oligonucleotide sequence (DNA or RNA) that can bind with corresponding ligands with high affinity and strong specificity. Currently, nucleic acid aptamers targeting BACE1 have been used to treat AD in vivo and in vitro.…”

Section: Introductionmentioning

confidence: 99%

BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer’s Disease in an APP-PS1 Animal Model

Wang

Zhu

Jia

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Alzheimer’s disease is a neurodegenerative disease caused by excessive amyloid β protein-induced neurotoxicity. However, drugs targeting amyloid β protein production face many problems, such as the low utilization rate of drugs by cells and the difficulty of drugs in penetrating the blood–brain barrier. A tetrahedral framework nucleic acid is a new type of nanonucleic acid structure that functions as a therapy and drug carrier. Here, we synthesized a BACE1 aptamer-modified tetrahedral framework nucleic acid and tested its therapeutic effect on Alzheimer’s disease in vitro and in vivo. Our results demonstrated that the tetrahedral framework nucleic acid could be used as a carrier to deliver the BACE1 aptamer to the brain to reduce the production of amyloid β proteins. It also played an antiapoptotic role by reducing the production of reactive oxygen species. Thus, this nanomaterial is a potential drug for Alzheimer’s disease.

show abstract

“…The SELEX technique has already been used for the selection of aptamers aiming to combat cancer, autoimmunological, and neurodegenerative as well as infectious diseases, such as bacterial and protozoal infections, among other applications [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. However, there is another, more neglected group of therapeutic targets that are related to viral infections.…”

Section: Introductionmentioning

confidence: 99%

Aptamer Applications in Emerging Viral Diseases

et al. 2021

View full text Add to dashboard Cite

Aptamers are single-stranded DNA or RNA molecules which are submitted to a process denominated SELEX. SELEX uses reiterative screening of a random oligonucleotide library to identify high-affinity binders to a chosen target, which may be a peptide, protein, or entire cells or viral particles. Aptamers can rival antibodies in target recognition, and benefit from their non-proteic nature, ease of modification, increased stability, and pharmacokinetic properties. This turns them into ideal candidates for diagnostic as well as therapeutic applications. Here, we review the recent accomplishments in the development of aptamers targeting emerging viral diseases, with emphasis on recent findings of aptamers binding to coronaviruses. We focus on aptamer development for diagnosis, including biosensors, in addition to aptamer modifications for stabilization in body fluids and tissue penetration. Such aptamers are aimed at in vivo diagnosis and treatment, such as quantification of viral load and blocking host cell invasion, virus assembly, or replication, respectively. Although there are currently no in vivo applications of aptamers in combating viral diseases, such strategies are promising for therapy development in the future.

show abstract

The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

Cited by 7 publications

References 43 publications

The Aptamer Ob2, a novel AChE inhibitor, restores cognitive deficits and alleviates amyloidogenesis in 5×FAD transgenic mice

The Aptamer Ob2, a novel AChE inhibitor, restores cognitive deficits and alleviates amyloidogenesis in 5×FAD transgenic mice

BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer’s Disease in an APP-PS1 Animal Model

Aptamer Applications in Emerging Viral Diseases

Contact Info

Product

Resources

About